Baseline demographic and clinical characteristics: full analysis set (n = 22). Values are n (%) unless otherwise specified.
| Characteristics | Placebo, n = 12 | POM 1 mg QD, n = 10 |
|---|---|---|
| Age, yrs, mean (SD) | 44.8 (13.8) | 49.8 (9.9) |
| Female | 10 (83.3) | 9 (90.0) |
| Race | ||
| White | 10 (83.3) | 7 (70.0) |
| Asian | 0 (0.0) | 2 (20.0) |
| Hawaiian Islander | 1 (8.3) | 0 (0.0) |
| Black | 0 (0.0) | 1 (10.0) |
| Missing | 1 (8.3) | 0 (0.0) |
| Weight, kg, mean (SD) | 80.5 (14.2) | 70.8 (25.2) |
| BMI, kg/m2, mean (SD) | 30.64 (5.4) | 26.67 (9.3) |
| Disease type | ||
| Diffuse | 9 (75.0) | 8 (80.0) |
| Limited | 3 (25.0) | 2 (20.0) |
| Calcium channel blockers | 2 (16.7) | 4 (40.0) |
| Systemic corticosteroids | 5 (41.7) | 7 (70.0) |
| Drugs for acid-related disorders* | 4 (33.3) | 7 (70.0) |
Note: The n reflects the no. randomized patients who received at least 1 dose of investigational study drug.
↵* Esomeprazole, omeprazole, pantoprazole, or sucralfate. POM: pomalidomide; QD: once daily; BMI: body mass index.